Key facts
- Procyon DX’s last known valuation is $2.6M (Oct 2025).
- It has raised $580K; the latest was Seed Round ($580K) in Oct 2025.
- Notable investors include Queen Mary University of London, Source Bioscience.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Procyon DX
- ·The full record, as it builds
Funding rounds
No funding rounds for Procyon DX are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Procyon DX
Developer of diagnostic tools designed for early disease detection. The company's platform analyzes protein biomarkers using advanced computational algorithms, integrates blood and urine sample processing, provides data-driven risk assessments, tracks biomarker changes over time, and offers predictive insights for multiple cancer types, enabling healthcare providers to deliver timely interventions, enhance diagnostic accuracy, improve patient outcomes, and support research in early disease detection.
- Sector
- Healthcare
- HQ
- Skipton, United Kingdom
- Founded
- 2025
- Website
- procyondx.com/
- Ownership
- Privately Held (backing)
Procyon DX doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Procyon DX shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Procyon DX in its N-PORT filings yet. We sweep new filings monthly.